AI-generated summary
The authors studied 30 patients with 37 atrophic scars from cutaneous leishmaniasis treated with a non-ablative fractional 1,540 nm laser, assessed by physicians and by patient self-report. They report statistically significant improvement in scar scores and patient satisfaction, with no persistent complications, and describe the laser as effective and safe.
- Participants
- 30
- Who or what was studied
- Patients with atrophic cutaneous leishmaniasis scars
- Limits stated in the abstract
- The abstract describes a single clinical trial with pre- and posttreatment measurements and no control group, and it does not report the magnitude of effect sizes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 540 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.